ArticlemAbs2018

Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

Alessandro Satta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.